PL1635799T3 - Kompozycje farmaceutyczne związków inhibitujących amyloid - Google Patents

Kompozycje farmaceutyczne związków inhibitujących amyloid

Info

Publication number
PL1635799T3
PL1635799T3 PL04744039T PL04744039T PL1635799T3 PL 1635799 T3 PL1635799 T3 PL 1635799T3 PL 04744039 T PL04744039 T PL 04744039T PL 04744039 T PL04744039 T PL 04744039T PL 1635799 T3 PL1635799 T3 PL 1635799T3
Authority
PL
Poland
Prior art keywords
pharmaceutical formulations
inhibiting compounds
amyloid
amyloid inhibiting
methods
Prior art date
Application number
PL04744039T
Other languages
English (en)
Inventor
Audley Legore
Denis Garceau
Original Assignee
Bellus Health International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health International Ltd filed Critical Bellus Health International Ltd
Publication of PL1635799T3 publication Critical patent/PL1635799T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04744039T 2003-06-23 2004-06-21 Kompozycje farmaceutyczne związków inhibitujących amyloid PL1635799T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48098403P 2003-06-23 2003-06-23
US51211603P 2003-10-17 2003-10-17
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
EP04744039A EP1635799B1 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds
PCT/IB2004/002381 WO2004112762A2 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (1)

Publication Number Publication Date
PL1635799T3 true PL1635799T3 (pl) 2010-01-29

Family

ID=33545348

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04744039T PL1635799T3 (pl) 2003-06-23 2004-06-21 Kompozycje farmaceutyczne związków inhibitujących amyloid

Country Status (18)

Country Link
US (2) US20050142191A1 (pl)
EP (2) EP2127648A1 (pl)
JP (1) JP4903561B2 (pl)
CN (1) CN103550196A (pl)
AT (1) ATE438391T1 (pl)
AU (2) AU2004248995B2 (pl)
BR (1) BRPI0411808A (pl)
CA (1) CA2529268C (pl)
DE (1) DE602004022408D1 (pl)
DK (1) DK1635799T3 (pl)
ES (1) ES2328818T3 (pl)
IL (1) IL172193A0 (pl)
MX (1) MXPA05013974A (pl)
NZ (1) NZ544685A (pl)
PL (1) PL1635799T3 (pl)
PT (1) PT1635799E (pl)
SI (1) SI1635799T1 (pl)
WO (1) WO2004112762A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
HK1051137A1 (zh) * 1999-07-09 2003-07-25 Isis Innovation Limited 抑制疾病的化合物和製備移植用的細胞
KR20050101537A (ko) * 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
US20060251714A1 (en) * 2005-04-12 2006-11-09 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
CA2673022A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2349233A4 (en) * 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION
WO2014109964A1 (en) 2013-01-08 2014-07-17 Rambus Inc. Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP7629182B2 (ja) 2020-10-02 2025-02-13 Ｏ－Ｆｏｒｃｅ合同会社 アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
US20250345298A1 (en) 2022-04-28 2025-11-13 Alzheon, Inc. Apoe4 correctors and methods of use
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4657704A (en) 1982-09-08 1987-04-14 Mitsui Toatsu Chemicals, Incorporated Production of aminoalkylsulfonic acids
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
EP0600973A1 (en) 1991-08-27 1994-06-15 The Upjohn Company A method for treatment of metabolic disorders and metabolism
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
EP0691844A1 (en) * 1993-03-29 1996-01-17 Queen's University At Kingston Method for treating amyloidosis
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ATE226090T1 (de) * 1994-04-22 2002-11-15 Yamanouchi Pharma Co Ltd Kolon-spezifisches arzneistofffreisetzungssystem
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
EP0957749A2 (en) * 1995-09-12 1999-11-24 The General Hospital Corporation Method for early detection of ovarian cancer
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DK1054664T3 (da) * 1998-02-11 2012-11-05 Bhi Ltd Partnership Fremgangsmåde til modulering af makrofagaktivering
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
IL139688A0 (en) * 1998-05-15 2002-02-10 Neurochem Inc Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
HK1051137A1 (zh) 1999-07-09 2003-07-25 Isis Innovation Limited 抑制疾病的化合物和製備移植用的細胞
CA2389973A1 (en) * 1999-11-04 2001-05-10 Andrx Corporation Method of treating amyloid beta precursor disorders
BR0016652A (pt) * 1999-12-23 2002-11-19 Neurochem Inc Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
FR2832928B1 (fr) * 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
US20050085553A1 (en) * 2001-12-26 2005-04-21 Masaomi Miyamato Remedies for mild recognition deflict
KR20050101537A (ko) * 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline

Also Published As

Publication number Publication date
ATE438391T1 (de) 2009-08-15
AU2004248995A1 (en) 2004-12-29
WO2004112762A2 (en) 2004-12-29
CA2529268C (en) 2013-10-29
JP2007518672A (ja) 2007-07-12
BRPI0411808A (pt) 2006-08-08
WO2004112762A3 (en) 2005-06-02
SI1635799T1 (sl) 2009-12-31
AU2004248995B2 (en) 2010-01-07
US20090182056A1 (en) 2009-07-16
EP2127648A1 (en) 2009-12-02
JP4903561B2 (ja) 2012-03-28
NZ544685A (en) 2009-05-31
AU2010201299A1 (en) 2010-04-22
US8835500B2 (en) 2014-09-16
EP1635799A2 (en) 2006-03-22
CN103550196A (zh) 2014-02-05
DE602004022408D1 (de) 2009-09-17
ES2328818T3 (es) 2009-11-18
EP1635799B1 (en) 2009-08-05
CA2529268A1 (en) 2004-12-29
MXPA05013974A (es) 2006-03-09
PT1635799E (pt) 2009-09-23
US20050142191A1 (en) 2005-06-30
IL172193A0 (en) 2009-02-11
DK1635799T3 (da) 2009-11-23

Similar Documents

Publication Publication Date Title
IL172193A0 (en) Pharmaceutical formulations of amyloid inhibiting compounds
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
PL1660057T3 (pl) Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
PL1862458T3 (pl) Środki lecznicze przydatne w leczeniu bólu
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
EP1500401A4 (en) DRUGS FOR THE TREATMENT OF VASCULAR DISEASES
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
TWI349549B (en) Medicament for treatment of intraocular angiopoietic disease
AU2003274649A8 (en) Diagnostic markers for therapeutic treatment
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease
GB0324283D0 (en) Therapeutic agents for the treatment of bone disorders
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders
GB0317241D0 (en) Therapeutic agents for the treatment of bone disorders
GB0217271D0 (en) Therapeutic treatment for tinnitus